Urothelial Carcinoma
Conditions
Interventions
Gold Standard:The clinical reference standard for patients with urothelial carcinoma, benign tumours of the urinary tract and other interfering cancers is pathological diagnosis, and patients with oth
Index test:Combined urine VIM and AL021918.2 gene methylation test
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients meeting any one of the following conditions can be included: (1) Patients with suspected symptoms of urinary tract epithelial cancer such as gross or microscopic hematuria, lumbar discomfort, urinary tract irritation symptoms, etc. (2) Patients with highly suspected or diagnosed urinary tract epithelial cancer based on clinical examination. (3) Patients with benign urinary system diseases (including benign urinary tract tumors, urinary calculi, effusion, infection, benign prostatic hyperplasia, cystitis, ureteritis, prostatitis, etc.) who plan to undergo or have already undergone imaging/endoscopic examination of the urinary system. (4) Untreated patients with other malignant tumors (including prostate cancer, renal cancer, colorectal cancer, cervical cancer, gastric cancer, liver cancer, lung cancer, breast cancer, thyroid cancer, etc.). (5) Postoperative urinary tract epithelial cancer patients who have undergone radical surgery for urinary tract epithelial cancer (with preoperative evaluation reagent detection).
Exclusion criteria
Exclusion criteria: Patients meeting any of the following conditions can be excluded: (1) Patients who have undergone surgery, radiotherapy/chemotherapy or other anti-tumor treatments in the past three months (except patients for preoperative and postoperative comparative studies); (2) Urinary tract epithelial cancer complicated with other malignant tumors (except for cases where primary urinary tract epithelial cancer has metastasized to other organs); (3) Samples not preserved as required; (4) The collected sample volume does not meet the detection requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity;Specificity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Positive coincidence rate;Negative coincidence rate; | — |
Countries
China
Contacts
Public ContactXuesong Li
Peking University First Hospital
Outcome results
None listed